Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Diseases × Mercaptopurine × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Rare Diseases 1 Oligodendroglioma 1 Neoplasms 1 Glioma 1 Genetic Diseases, Inborn 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Streptozocin 1 Specimen Handling 1 Radiosurgery 1 Radiation 1 Nivolumab 1 Mercaptopurine 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 Carmustine 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡